Home » Stocks » Fusion Pharmaceuticals

Fusion Pharmaceuticals, Inc. (FUSN)

Stock Price: $12.40 USD -0.18 (-1.43%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 516.63M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 41.66M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $12.40
Previous Close $12.58
Change ($) -0.18
Change (%) -1.43%
Day's Open 12.62
Day's Range 12.40 - 12.74
Day's Volume 17,606
52-Week Range 12.19 - 19.00

More Stats

Market Cap 516.63M
Enterprise Value 195.96M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 41.66M
Float 16.69M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.64
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 320.67M
Net Cash / Share 7.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(96.21% upside)
Current: $12.40
Target: 24.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-18.22-10.10-6.99
Net Income-16.19-11.65-6.26
Shares Outstanding1.921.871.87
Earnings Per Share-8.45-6.22-3.34
Operating Cash Flow-13.69-9.87-6.13
Capital Expenditures-0.46-1.12-0.10
Free Cash Flow-14.15-10.99-6.22
Cash & Equivalents67.1229.080.00
Net Cash / Debt67.1229.080.00
Book Value-33.49-17.92-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fusion Pharmaceuticals, Inc.
Country Canada
Employees 41
CEO John Valliant

Stock Information

Ticker Symbol FUSN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FUSN
IPO Date June 26, 2020


Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada. Address: